Evidence map›Paper›PMID 42773313›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Re-irradiation using boron neutron capture therapy for recurrent oral squamous cell carcinoma: the impact of tumor volume and early response on survival.

Kanako Takayama, Ichiro Seto, Takashi Ono, Yoshiaki Takagawa, Shinya Komori, Ryohei Kato, Akihiko Takeuchi, Yuhei Yamazaki, Tomoaki Motoyanagi, Yuki Narita and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kanako TakayamaDepartment of Radiation Oncology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan. kanaproton@gmail.com.ORCID http://orcid.org/0000-0002-4622-0768
Ichiro SetoDepartment of Radiation Oncology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Takashi OnoDepartment of Radiation Oncology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Yoshiaki TakagawaDepartment of Radiation Oncology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Shinya KomoriDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Ryohei KatoDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Akihiko TakeuchiDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Yuhei YamazakiDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Tomoaki MotoyanagiDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Yuki NaritaDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Shunsuke KomatsuDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Takahiro KatoDepartment of Radiation Physics and Technology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.
Yoshihiro TakaiDepartment of Radiation Oncology, Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRe-irradiation for recurrent oral cancer remains clinically challenging due to limited treatment efficacy and severe toxicity. In this study, we evaluated the clinical outcomes of boron neutron capture therapy (BNCT) and explored prognostic factors associated with survival in oral squamous cell carcinoma (OSCC).

methodsWe conducted a retrospective single-institution cohort study of 45 patients with recurrent OSCC treated with accelerator-based BNCT between June 2020 and December 2022. Overall survival (OS), local control (LC), and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Prognostic factors were assessed using Cox proportional hazards models.

resultsThe objective response rate was 80%. At a median follow-up of 25 months, the 2‑year OS, LC, and PFS rates were 51.1%, 31.8%, and 22.2%, respectively. In the univariate analysis, tumor volume was associated with OS (p = 0.036). Exploratory analyses suggested that tumor volumes ≥ 20 cm

conclusionBNCT may be an option for selected patients with recurrent OSCC after prior irradiation. Favorable responses and OS were observed, although LC remained limited and toxicities required careful management. Baseline tumor volume warrants further study for survival risk stratification, while early response may aid prognostic assessment.

Indexed as

Boron neutron capture therapyEarly responseOral squamous cell carcinomaPrognostic factorsRe-irradiationTumor volume

Identifiers

PMID42773313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.